Potential of adiponectin as a cardioprotective agent

Bibliography

• 1  Friedman JM: A war on obesity, not the obese. Science299(5608),856–858 (2003).
  Medline CASGoogle Scholar
• 2  Reilly MP, Rader DJ: The metabolic syndrome: more than the sum of its parts? Circulation108(13),1546–1551 (2003).
  MedlineGoogle Scholar
• 3  Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K: Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol.14(6),561–566 (2003).
  Medline CASGoogle Scholar
• 4  Berg AH, Scherer PE: Adipose tissue, inflammation, and cardiovascular disease. Circ. Res.96(9),939–949 (2005).
  Medline CASGoogle Scholar
• 5  Yang Q, Graham TE, Mody N et al.: Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type 2 diabetes. Nature436(7049),356–362 (2005).
  Medline CASGoogle Scholar
• 6  Kanda H, Tateya S, Tamori Y et al.: MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest.116(6),1494–1505 (2006).
  Medline CASGoogle Scholar
• 7  Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem. Biophys. Res. Commun.221(2),286–289 (1996).
  Medline CASGoogle Scholar
• 8  Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem.270(45),26746–26749 (1995).
  Medline CASGoogle Scholar
• 9  Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem.271(18),10697–10703 (1996).
  Medline CASGoogle Scholar
• 10  Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. (Tokyo)120(4),803–812 (1996).
  Medline CASGoogle Scholar
• 11  Arita Y, Kihara S, Ouchi N et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun.257(1),79–83 (1999).
  Medline CASGoogle Scholar
• 12  Pajvani UB, Du X, Combs TP et al.: Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J. Biol. Chem.278(11),9073–9085 (2003).
  Medline CASGoogle Scholar
• 13  Kishida K, Nagaretani H, Kondo H et al.: Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochem. Biophys. Res. Commun.306(1),286–292 (2003).
  Medline CASGoogle Scholar
• 14  Fruebis J, Tsao TS, Javorschi S et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci. USA98(4),2005–2010 (2001).
  Medline CASGoogle Scholar
• 15  Hotta K, Funahashi T, Bodkin NL et al.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to Type 2 diabetes in rhesus monkeys. Diabetes50(5),1126–1133 (2001).
  Medline CASGoogle Scholar
• 16  Ryo M, Nakamura T, Kihara S et al.: Adiponectin as a biomarker of the metabolic syndrome. Circ. J.68(11),975–981 (2004).
  Medline CASGoogle Scholar
• 17  Cnop M, Havel PJ, Utzschneider KM et al.: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia46(4),459–469 (2003).
  Medline CASGoogle Scholar
• 18  Hotta K, Funahashi T, Arita Y et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol.20(6),1595–1599 (2000).
  Medline CASGoogle Scholar
• 19  Lindsay RS, Funahashi T, Hanson RL et al.: Adiponectin and development of Type 2 diabetes in the Pima Indian population. Lancet360(9326),7–8 (2002).
  MedlineGoogle Scholar
• 20  Spranger J, Kroke A, Mohlig M et al.: Adiponectin and protection against Type 2 diabetes mellitus. Lancet361(9353),226–228 (2003).
  Medline CASGoogle Scholar
• 21  Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A: Plasma adiponectin is an independent predictor of Type 2 diabetes in Asian Indians. Diabetes Care26(12),3226–3229 (2003).
  MedlineGoogle Scholar
• 22  Choi KM, Lee J, Lee KW et al.: Serum adiponectin concentrations predict the developments of Type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin. Endocrinol. (Oxf.)61(1),75–80 (2004).
  Medline CASGoogle Scholar
• 23  Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T: Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J. Clin. Endocrinol. Metab.89(1),87–90 (2004).
  Medline CASGoogle Scholar
• 24  Ouchi N, Kihara S, Arita Y et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation100(25),2473–2476 (1999).
  Medline CASGoogle Scholar
• 25  Kumada M, Kihara S, Sumitsuji S et al.: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol.23(1),85–89 (2003).
  Medline CASGoogle Scholar
• 26  Iwashima Y, Katsuya T, Ishikawa K et al.: Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension43(6),1318–1323 (2004).
  Medline CASGoogle Scholar
• 27  Nakamura Y, Shimada K, Fukuda D et al.: Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart90(5),528–533 (2004).
  Medline CASGoogle Scholar
• 28  Kojima S, Funahashi T, Sakamoto T et al.: The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart89(6),667 (2003).
  Medline CASGoogle Scholar
• 29  Kojima S, Funahashi T, Otsuka F et al.: Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis (2006) (Epub ahead of print).
  Google Scholar
• 30  Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA291(14),1730–1737 (2004).
  Medline CASGoogle Scholar
• 31  Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB: Adiponectin and future coronary heart disease events among men with Type 2 diabetes. Diabetes54(2),534–539 (2005).
  Medline CASGoogle Scholar
• 32  Zoccali C, Mallamaci F, Tripepi G et al.: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J. Am. Soc. Nephrol.13(1),134–141 (2002).
  Medline CASGoogle Scholar
• 33  Lindsay RS, Resnick HE, Zhu J et al.: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler. Thromb. Vasc. Biol.25(3),e15–e16 (2005).
  Medline CASGoogle Scholar
• 34  Lawlor DA, Davey Smith G, Ebrahim S, Thompson C, Sattar N: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J. Clin. Endocrinol. Metab.90(10),5677–5683 (2005).
  Medline CASGoogle Scholar
• 35  Sattar N, Wannamethee G, Sarwar N et al.: Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation114(7),623–629 (2006).
  Medline CASGoogle Scholar
• 36  Furuhashi M, Ura N, Moniwa N et al.: Possible impairment of transcardiac utilization of adiponectin in patients with Type 2 diabetes. Diabetes Care27(9),2217–2221 (2004).
  MedlineGoogle Scholar
• 37  Takano H, Kodama Y, Kitta Y et al.: Transcardiac adiponectin gradient is independently related to endothelial vasomotor function in large and resistance coronary arteries in humans. Am. J. Physiol. Heart Circ. Physiol.291(6),H2641–H2646 (2006).
  Medline CASGoogle Scholar
• 38  Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM: Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press.13(4),236–242 (2004).
  Medline CASGoogle Scholar
• 39  Mitsuhashi H, Yatsuya H, Tamakoshi K et al.: Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension49(6),1448–1454 (2007).
  Medline CASGoogle Scholar
• 40  Kistorp C, Faber J, Galatius S et al.: Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation112(12),1756–1762 (2005).
  Medline CASGoogle Scholar
• 41  George J, Patal S, Wexler D et al.: Circulating adiponectin concentrations in patients with congestive heart failure. Heart92(10),1420–1424 (2006).
  Medline CASGoogle Scholar
• 42  Tsutamoto T, Tanaka T, Sakai H et al.: Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur. Heart J.28(14),1723–1730 (2007).
  MedlineGoogle Scholar
• 43  Anker SD, Rauchhaus M: Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. Curr. Opin. Cardiol.14(3),211–216 (1999).
  Medline CASGoogle Scholar
• 44  Mosterd A, Cost B, Hoes AW et al.: The prognosis of heart failure in the general population: the Rotterdam Study. Eur. Heart J.22(15),1318–1327 (2001).
  Medline CASGoogle Scholar
• 45  Ingelsson E, Riserus U, Berne C et al.: Adiponectin and risk of congestive heart failure. JAMA295(15),1772–1774 (2006).
  Medline CASGoogle Scholar
• 46  Okamoto Y, Kihara S, Ouchi N et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation106(22),2767–2770 (2002).
  Medline CASGoogle Scholar
• 47  Kobashi C, Urakaze M, Kishida M et al.: Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res.97(12),1245–1252 (2005).
  Medline CASGoogle Scholar
• 48  Ouchi N, Kihara S, Arita Y et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation102(11),1296–1301 (2000).
  Medline CASGoogle Scholar
• 49  Ouchi N, Kihara S, Arita Y et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation103(8),1057–1063 (2001).
  Medline CASGoogle Scholar
• 50  Yokota T, Oritani K, Takahashi I et al.: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood96(5),1723–1732 (2000).
  Medline CASGoogle Scholar
• 51  Kumada M, Kihara S, Ouchi N et al.: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation109(17),2046–2049 (2004).
  Medline CASGoogle Scholar
• 52  Kubota N, Terauchi Y, Yamauchi T et al.: Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem.277(29),25863–25866 (2002).
  Medline CASGoogle Scholar
• 53  Matsuda M, Shimomura I, Sata M et al.: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J. Biol. Chem.277(40),37487–37491 (2002).
  Medline CASGoogle Scholar
• 54  Arita Y, Kihara S, Ouchi N et al.: Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation105(24),2893–2898 (2002).
  Medline CASGoogle Scholar
• 55  Wang Y, Lam KS, Xu JY et al.: Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem.280(18),18341–18347 (2005).
  Medline CASGoogle Scholar
• 56  Chorny M, Polyak B, Alferiev IS, Walsh K, Friedman G, Levy RJ: Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles. FASEB J.21(10),2510–2519 (2007).
  Medline CASGoogle Scholar
• 57  Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K: Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. J. Biol. Chem.279(27),28670–28674 (2004).
  Medline CASGoogle Scholar
• 58  Ouchi N, Kobayashi H, Kihara S et al.: Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem.279(2),1304–1309 (2004).
  Medline CASGoogle Scholar
• 59  Brakenhielm E, Veitonmaki N, Cao R et al.: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA101(8),2476–2481 (2004).
  Medline CASGoogle Scholar
• 60  Sata M, Nishimatsu H, Osuga J et al.: Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension43(6),1214–1220 (2004).
  Medline CASGoogle Scholar
• 61  Kobayashi H, Ouchi N, Kihara S et al.: Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res.94(4),e27–e31 (2004).
  Medline CASGoogle Scholar
• 62  Xi W, Satoh H, Kase H, Suzuki K, Hattori Y: Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production: vasorelaxation in response to globular adiponectin. Biochem. Biophys. Res. Commun.332(1),200–205 (2005).
  Medline CASGoogle Scholar
• 63  Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem.278(45),45021–45026 (2003).
  Medline CASGoogle Scholar
• 64  Hattori Y, Suzuki M, Hattori S, Kasai K: Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia46(11),1543–1549 (2003).
  Medline CASGoogle Scholar
• 65  Motoshima H, Wu X, Mahadev K, Goldstein BJ: Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun.315(2),264–271 (2004).
  Medline CASGoogle Scholar
• 66  Ouchi N, Ohishi M, Kihara S et al.: Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension42(3),231–234 (2003).
  Medline CASGoogle Scholar
• 67  Ohashi K, Kihara S, Ouchi N et al.: Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension47(6),1108–1116 (2006).
  Medline CASGoogle Scholar
• 68  Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD: Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest.97(11),2601–2610 (1996).
  Medline CASGoogle Scholar
• 69  Al Suwaidi J, Higano ST, Holmes DR Jr, Lennon R, Lerman A: Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J. Am. Coll. Cardiol.37(6),1523–1528 (2001).
  Medline CASGoogle Scholar
• 70  Ilercil A, Devereux RB, Roman MJ et al.: Relationship of impaired glucose tolerance to left ventricular structure and function: the Strong Heart Study. Am. Heart J.141(6),992–998 (2001).
  Medline CASGoogle Scholar
• 71  Rutter MK, Parise H, Benjamin EJ et al.: Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation107(3),448–454 (2003).
  Medline CASGoogle Scholar
• 72  Shibata R, Ouchi N, Ito M et al.: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med.10(12),1384–1389 (2004).
  Medline CASGoogle Scholar
• 73  Liao Y, Takashima S, Maeda N et al.: Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res.67(4),705–713 (2005).
  Medline CASGoogle Scholar
• 74  Fujioka D, Kawabata KI, Saito Y et al.: Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am. J. Physiol. Heart Circ. Physiol.290(6),H2409–H2416 (2006).
  Medline CASGoogle Scholar
• 75  Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR: Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem.279(31),32771–32779 (2004).
  Medline CASGoogle Scholar
• 76  Pineiro R, Iglesias MJ, Gallego R et al.: Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett.579(23),5163–5169 (2005).
  Medline CASGoogle Scholar
• 77  Palanivel R, Fang X, Park M et al.: Globular and full-length forms of adiponectin mediate specific changes in glucose and fatty acid uptake and metabolism in cardiomyocytes. Cardiovasc. Res.75(1),148–157 (2007).
  Medline CASGoogle Scholar
• 78  Hattori Y, Hattori S, Akimoto K et al.: Globular adiponectin activates nuclear factor-κB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes56(3),804–808 (2007).
  Medline CASGoogle Scholar
• 79  Orlander PR, Goff DC, Morrissey M et al.: The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican–Americans and non-Hispanic Whites. The Corpus Christi Heart Project. Diabetes43(7),897–902 (1994).
  Medline CASGoogle Scholar
• 80  Wolk R, Berger P, Lennon RJ, Brilakis ES, Somers VK: Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation108(18),2206–2211 (2003).
  MedlineGoogle Scholar
• 81  Shibata R, Sato K, Pimentel DR et al.: Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med.11(10),1096–1103 (2005).
  Medline CASGoogle Scholar
• 82  Tao L, Gao E, Jiao X et al.: Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation115(11),1408–1416 (2007).
  Medline CASGoogle Scholar
• 83  Shibata R, Sato K, Kumada M et al.: Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc. Res.74(3),471–479 (2007).
  Medline CASGoogle Scholar
• 84  Li J, Miller EJ, Ninomiya-Tsuji J, Russell RR 3rd, Young LH: AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ. Res.97(9),872–879 (2005).
  Medline CASGoogle Scholar
• 85  Russell RR 3rd, Li J, Coven DL et al.: AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest.114(4),495–503 (2004).
  Medline CASGoogle Scholar
• 86  Terai K, Hiramoto Y, Masaki M et al.: AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol. Cell. Biol.25(21),9554–9575 (2005).
  Medline CASGoogle Scholar
• 87  Bolli R, Shinmura K, Tang XL et al.: Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc. Res.55(3),506–519 (2002).
  Medline CASGoogle Scholar
• 88  Camitta MG, Gabel SA, Chulada P et al.: Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation104(20),2453–2458 (2001).
  Medline CASGoogle Scholar
• 89  Xiao CY, Yuhki K, Hara A et al.: Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation109(20),2462–2468 (2004).
  Medline CASGoogle Scholar
• 90  Hohlfeld T, Meyer-Kirchrath J, Vogel YC, Schror K: Reduction of infarct size by selective stimulation of prostaglandin EP(3) receptors in the reperfused ischemic pig heart. J. Mol. Cell. Cardiol.32(2),285–296 (2000).
  Medline CASGoogle Scholar
• 91  Bresalier RS, Sandler RS, Quan H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352(11),1092–1102 (2005).
  Medline CASGoogle Scholar
• 92  Solomon SD, McMurray JJ, Pfeffer MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med.352,1071–1080 (2005).
  Medline CASGoogle Scholar
• 93  Takahashi T, Saegusa S, Sumino H et al.: Adiponectin replacement therapy attenuates myocardial damage in leptin-deficient mice with viral myocarditis. J. Int. Med. Res.33(2),207–214 (2005).
  Medline CASGoogle Scholar
• 94  Shibata R, Izumiya Y, Sato K et al.: Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol.42(6),1065–1074 (2007).
  Medline CASGoogle Scholar
• 95  Yamauchi T, Kamon J, Ito Y et al.: Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature423(6941),762–769 (2003).
  Medline CASGoogle Scholar
• 96  Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl Acad. Sci. USA101(28),10308–10313 (2004).
  Medline CASGoogle Scholar
• 97  Takemura Y, Ouchi N, Shibata R et al.: Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J. Clin. Invest.117(2),375–386 (2007).
  Medline CASGoogle Scholar
• 98  Kudrjashova E, Bashtrikov P, Bochkov V et al.: Expression of adhesion molecule T-cadherin is increased during neointima formation in experimental restenosis. Histochem. Cell Biol.118(4),281–290 (2002).
  Medline CASGoogle Scholar
• 99  Lord E, Ledoux S, Murphy BD, Beaudry D, Palin MF: Expression of adiponectin and its receptors in swine. J. Anim. Sci.83(3),565–578 (2005).
  Medline CASGoogle Scholar
• 100  Takahashi T, Saegusa S, Sumino H et al.: Adiponectin, T-cadherin and tumour necrosis factor-α in damaged cardiomyocytes from autopsy specimens. J. Int. Med. Res.33(2),236–244 (2005).
  Medline CASGoogle Scholar
• 101  Michalak M, Guo L, Robertson M, Lozak M, Opas M: Calreticulin in the heart. Mol. Cell. Biochem.263(1–2),137–142 (2004).
  Medline CASGoogle Scholar
• 102  Ding G, Qin Q, He N et al.: Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor γ. J. Mol. Cell. Cardiol.43(1),73–84 (2007).
  Medline CASGoogle Scholar
• 103  Yoda-Murakami M, Taniguchi M, Takahashi K et al.: Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem. Biophys. Res. Commun.285(2),372–377 (2001).
  Medline CASGoogle Scholar
• 104  Delaigle AM, Senou M, Guiot Y, Many MC, Brichard SM: Induction of adiponectin in skeletal muscle of Type 2 diabetic mice: in vivo and in vitro studies. Diabetologia49(6),1311–1323 (2006).
  Medline CASGoogle Scholar
• 105  Takahashi T, Zhu SJ, Sumino H et al.: Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci.78(2),195–204 (2005).
  Medline CASGoogle Scholar
• 106  Takahashi T, Yu F, Saegusa S et al.: Impaired expression of cardiac adiponectin in leptin-deficient mice with viral myocarditis. Int. Heart J.47(1),107–123 (2006).
  Medline CASGoogle Scholar
• 107  Wittchen F, Suckau L, Witt H et al.: Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets. J. Mol. Med.85(3),253–267 (2007).
  Google Scholar